Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (DFPH) Return on Equity (2020 - 2025)

Historic Return on Equity for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to 6.24%.

  • Oncology Institute's Return on Equity rose 93800.0% to 6.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.24%, marking a year-over-year increase of 93800.0%. This contributed to the annual value of 2.13% for FY2024, which is 12100.0% down from last year.
  • As of Q3 2025, Oncology Institute's Return on Equity stood at 6.24%, which was up 93800.0% from 33.65% recorded in Q2 2025.
  • Oncology Institute's 5-year Return on Equity high stood at 33.65% for Q2 2025, and its period low was 14.87% during Q1 2025.
  • For the 5-year period, Oncology Institute's Return on Equity averaged around 0.39%, with its median value being 0.39% (2021).
  • Within the past 5 years, the most significant YoY rise in Oncology Institute's Return on Equity was 356800bps (2025), while the steepest drop was -133800bps (2025).
  • Quarter analysis of 5 years shows Oncology Institute's Return on Equity stood at 0.14% in 2021, then surged by 101bps to 0.0% in 2022, then plummeted by -106585bps to 1.29% in 2023, then plummeted by -426bps to 6.78% in 2024, then surged by 192bps to 6.24% in 2025.
  • Its Return on Equity stands at 6.24% for Q3 2025, versus 33.65% for Q2 2025 and 14.87% for Q1 2025.